Skip to content

Ketamine: all studies

Page 94 of 448: studies 931 to 940 of 4,475, newest first. Back to the ketamine overview

Research

Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis

medRxiv Preprint Server March 21, 2025 Leo R. Silberbauer, Benjamin Eggerstorfer, Paul Michenthaler et al. 1 citation preprint

Background Ketamine represents a significant advancement in antidepressant therapy, but the commonly used intravenous and intranasal application routes currently limit its availability beyond specialized centers. By contrast, oral ketamine treatment might constitute an alternative that is easy to administer with established safety and efficacy for patients with chronic and severe pain at home.

DOI: 10.1101/2025.03.21.25324252 (opens in new tab) Full text (opens in new tab) Depression treatment Mental health management Mood disorder therapy Antidepressant care +18

N-Acetylcysteine Mitigates Ketamine Neurotoxicity in Young Rats by Modulating ROS-Mediated Pyroptosis and Ferroptosis.

Molecular Neurobiology March 20, 2025 Hui Bai, Hui Chen, Shan Du et al. 4 citations

Ketamine, an N-methyl-D-aspartate receptor antagonist with anesthetic and analgesic properties, is extensively utilized for the induction and maintenance of pediatric perioperative anesthesia. Increasing evidence suggests that prolonged exposure to ketamine may induce neurotoxicity in developing animals, adversely affecting their long-term cognitive function. N-acetylcysteine (NAC) is an...

DOI: 10.1007/s12035-025-04860-2 (opens in new tab) Full text (opens in new tab) Ketamine Pediatric anesthesia Oxidative stress Brain development +7

Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis.

Journal of Eating Disorders March 17, 2025 Paula J Escobedo-Aedo, Chris Serrand, Sarah Kabani et al. 4 citations

Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic in depression and suicidal ideations, could be an innovative adjuvant treatment for the AN spectrum. We describe a case series...

DOI: 10.1186/s40337-025-01232-y (opens in new tab) Full text (opens in new tab) Ketamine therapy Eating disorder treatment Mental health research Anorexia treatment +5

Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.

Biological Psychiatry March 15, 2025 Anna Onisiforou, Andria Michael, Markos Apostolakis et al. 14 citations

Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing high levels of opioid use and related fatalities. Although currently prescribed medications for OUD are considered lifesaving, they inadequately address negative affect and cognitive impairment, resulting in high relapse rates to nonmedical opioid use even years after drug cessation (protracted abstinence)....

DOI: 10.1016/j.biopsych.2024.09.008 (opens in new tab) Full text (opens in new tab) Hydroxynorketamine Opioid crisis Opioid use disorders Relapse +4

Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

Journal of Affective Disorders March 15, 2025 Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros et al. 24 citations

Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a...

DOI: 10.1016/j.jad.2024.12.036 (opens in new tab) Full text (opens in new tab) Depression Adrenocorticotropic hormone Corticotropin releasing factor Cortisol +4

Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.

Journal of Affective Disorders March 15, 2025 Kevin H. Yang, Wayne Kepner, Charles M Cleland et al. 19 citations

Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored. We analyzed data from the 2015-2022 National Survey on Drug Use and Health focusing on adults in the US. Trends in past-year ketamine use, overall and by depression status, were...

DOI: 10.1016/j.jad.2024.12.108 (opens in new tab) Full text (opens in new tab) Depression Nationally representative samples Ketamine-use-trends Mental-health-epidemiology +2

Using cluster analysis to investigate consumption patterns in cases positive to ketamine: a national 7-year study.

Naunyn-Schmiedeberg's Archives of Pharmacology March 14, 2025 Shyh-Yuh Wei, Chien-Chou Su, Hsuan-Yun Hu et al. 1 citation

The use of ketamine has increased; however, actual consumption patterns and ketamine-related deaths remain poorly understood. This study aimed to (1) cluster the consumption patterns of individuals who consume ketamine and (2) investigate their associations with manner and cause of death. A retrospective study was conducted on all cases positive to ketamine at death, retrieved from the...

DOI: 10.1007/s00210-025-04019-9 (opens in new tab) Full text (opens in new tab) Substance abuse Drug interactions Addiction research Toxicology +6

Fine-tuning of dopamine receptor signaling with aripiprazole counteracts ketamine's dissociative action, but not its antidepressant effect.

Translational Psychiatry March 8, 2025 Daiki Nakatsuka, Taro Suwa, Yuichi Deguchi et al. 1 citation

Ketamine, a rapid-acting antidepressant, has undesirable psychotomimetic effects, including a dissociative effect. There is currently no effective strategy to suppress these side effects while preserving its antidepressant effect. Here, we investigated the effects of a D2/D3 receptor antagonist and partial agonists on the psychotomimetic and antidepressant effects of ketamine in mice and...

DOI: 10.1038/s41398-025-03284-9 (opens in new tab) Full text (opens in new tab) Ketamine therapy Antidepressant medication Mental health treatment Psychiatric research +1

Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction.

Journal of Addictive Diseases March 6, 2025 Christopher Lomas 2 citations

This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic interventions. Patterns of misuse demonstrate the complex interplay of neurobiological, socio-economic, demographic and psychological factors with adolescents, women and polysubstance users identified as high-risk groups. Neurobiological findings...

Effect of esketamine on reducing postpartum pain and depression.

World Journal of Clinical Cases March 6, 2025 Brandon P Lucke-Wold, Armin Karamian 9 citations

In this editorial, we comment on a recent article by Chen et al, that addressed the effect of intraoperative injection of esketamine on postoperative analgesia and postoperative rehabilitation after cesarean section. Poor management of post-cesarean pain is associated with decreased maternal care for the baby, longer hospitalization, and higher risk of developing postpartum depression....

DOI: 10.12998/wjcc.v13.i7.100422 (opens in new tab) Full text (opens in new tab) Cesarean-section c-section Esketamine-therapy ketamine treatment Postpartum-depression postnatal depression Baby blues +8